CA
TEVA icon

Claris Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Claris Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,097
Closed -$19.8K – 1032
2024
Q3 		$19.8K Buy
+1,097
New +$19.2K 0.01% 187

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Claris Advisors's TEVA Position: Q4 2024 in Review

Claris Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 1,097 shares — an estimated $19.8K sold.

Claris Advisors first reported a position in TEVA in Q3 2024 and held it in 1 quarter. The position peaked at $19.8K in Q3 2024. 583 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Claris Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 1,097 Teva Pharmaceuticals shares in Q4 2024, an estimated $19.8K.
  • Claris Advisors first reported a position in Teva Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Teva Pharmaceuticals position peaked at $19.8K in Q3 2024.
  • 583 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.